Major HER2-Positive Breast Cancer Trial Identifies Patients Who May Respond to Less Intensive Chemotherapy

HER2-positive breast cancers can be aggressive, but targeted therapies have substantially improved treatment outcomes. Researchers are now investigating whether some patients can achieve excellent responses without undergoing unnecessarily intensive chemotherapy.

The CompassHER2-pCR study examined patients receiving a neoadjuvant regimen consisting of one chemotherapy drug together with two HER2-targeted medicines. Researchers identified clinical and molecular characteristics associated with pathological complete response, meaning no remaining invasive cancer can be detected in the surgical specimen after pre-surgical treatment.

The findings could eventually help oncologists better determine which patients may be candidates for reduced treatment intensity while maintaining effective cancer control. However, researchers are continuing follow-up to determine whether patients who achieve complete response maintain favorable long-term recurrence-free survival.

This is important because reducing unnecessary chemotherapy exposure could potentially decrease treatment-related complications while preserving cancer treatment effectiveness.